Long-term efficacy of imatinib mesylate in patients with advanced Tenosynovial Giant Cell Tumor

Tenosynovial giant cell tumors (TGCT), are rare colony stimulating factor-1(CSF-1)-driven proliferative disorders affecting joints. Diffuse-type TGCT often causes significant morbidity due to local recurrences necessitating multiple surgeries. Imatinib mesylate (IM) blocks the CSF-1 receptor. This s...

Descripción completa

Detalles Bibliográficos
Autores principales: Verspoor, F. G. M., Mastboom, M. J. L., Hannink, G., Maki, R. G., Wagner, A., Bompas, E., Desai, J., Italiano, A., Seddon, B. M., van der Graaf, W. T. A., Blay, J.-Y., Brahmi, M., Eberst, L., Stacchiotti, S., Mir, O., van de Sande, M. A. J., Gelderblom, H., Cassier, P. A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6786996/
https://www.ncbi.nlm.nih.gov/pubmed/31601938
http://dx.doi.org/10.1038/s41598-019-51211-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6786996/
https://www.ncbi.nlm.nih.gov/pubmed/31601938
http://dx.doi.org/10.1038/s41598-019-51211-y

Ejemplares similares